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Objective: The objective of this study is to investigate if bone
marrow–derived cells (BMCs) regenerate vascular tissues and im-
prove patency in tissue-engineered small-diameter (internal diame-
ter  3 mm) vascular grafts.
Summary Background Data: BMCs have demonstrated the ability
to differentiate into endothelial-like cells and vascular smooth mus-
cle–like cells and may offer an alternative cell source for vascular
tissue engineering. Thus, we tissue-engineered small-diameter vas-
cular grafts with BMCs and decellularized arteries.
Methods: Canine BMCs were differentiated in vitro into smooth
muscle -actin/smooth muscle myosin heavy-chain-positive cells
and von Willebrand factor/CD31-positive cells and seeded onto
decellularized canine carotid arteries (internal diameter  3 mm).
The seeded grafts were implanted in cell donor dogs. The vascular-
tissue regeneration and graft patency were investigated with immu-
nohistochemistry and angiography, respectively.
Results: The vascular grafts seeded with BMCs remained patent for
up to 8 weeks in the canine carotid artery interposition model,
whereas nonseeded grafts occluded within 2 weeks. Within 8 weeks
after implantation, the vascular grafts showed regeneration of the 3
elements of artery (endothelium, media, and adventitia). BMCs
labeled with a fluorescent dye prior to implantation were detected in
the retrieved vascular grafts, indicating that the BMCs participated
in the vascular tissue regeneration.
Conclusions: Here we show that BMCs have the potential to
regenerate vascular tissues and improve patency in tissue-engi-
neered small-diameter vascular grafts. This is the first report of a
small-diameter neovessel engineered with BMCs as a cell source.
(Ann Surg 2005;241: 506–515)
Therapies for coronary artery disease and peripheral vasculardisease often require replacement of the diseased vessels
with vascular grafts. Autologous arteries or veins are the best
substitutes for small-diameter (internal diameter ID  6 mm)
vessels.1 However, many patients do not have vessels suitable
for grafting due to preexisting vascular diseases or vessel use
in previous procedures. Therefore, there have been attempts
to develop a small-diameter vascular graft made of synthetic
or natural polymers. The synthetic polymeric materials in-
clude polyethylene terephthalate and expanded polytetrafluo-
roethylene (ePTFE).2 Although these polymeric vascular
grafts have been successfully employed to replace blood
vessels above 6 mm in ID, these polymeric grafts cannot be
used for treatment of small-diameter vascular diseases due to
thrombus formation.3,4 Coating of the intimal side with anti-
thrombogenic materials, such as heparin,5 polyethylene ox-
ide,6 or endothelial cells (ECs),7 has been applied to solve
this problem, but these approaches were unsuccessful. A
decellularized tissue matrix has been shown to be success-
fully remodeled into cellularized vessels after implantation in
rabbits.8 However, this result may not be relevant to humans,
because endothelial-cell development on vascular grafts in
humans is much slower than in rabbits.9
Recently, tissue-engineering techniques have been ap-
plied to develop small-diameter vascular grafts. Several stud-
ies have fabricated small-diameter vascular grafts by cultur-
ing smooth muscle cells (SMCs) and ECs,10–12 which were
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isolated from autologous blood vessels, either on biodegrad-
able polymer scaffolds or without exogenous materials, but
these grafts developed thrombosis shortly after implanta-
tion.11,12 Another drawback of this approach is that the graft
fabrication procedures involve a blood vessel biopsy to obtain
vascular cell sources, which may result in potential morbidity
at the donor sites and could be limited by a healthy autolo-
gous vessel shortage. Another cell source for tissue engineer-
ing of vascular grafts is multipotent stem cell. Recently,
vascular grafts fabricated by seeding endothelial progenitor
cells (EPCs) derived from peripheral blood onto decellular-
ized vessels were shown to maintain patency for 130 days in
the ovine model.13 However, seeding only with EPCs would
not induce complete smooth muscle (SM) regeneration in the
arterial grafts.
Bone marrow–derived cells (BMCs) could be an alter-
native stem cell source for vascular tissue engineering. BMCs
have demonstrated the ability to differentiate into multiple
mesenchymal cell lineages.14,15 Recently, BMCs have been
shown to differentiate into endothelial-like cells16–19 and
vascular SM-like cells.20–23 Furthermore, several studies
have demonstrated that bone marrow mononuclear cells
(BMMNCs) contribute to histogenesis of tissue-engineered
large-diameter vascular grafts24 and that bone marrow CD34-
positive cells enhance the graft endothelialization in vivo.25
In this study, we attempted to develop small-diameter
(ID  3 mm) vascular grafts using BMCs and showed that
BMC seeding significantly improved the patency of tissue-
engineered small-diameter vascular grafts. Small-diameter
blood vessels were fabricated by seeding 2 types of vascular
cells differentiated from autologous BMMNCs onto decellu-
larized carotid arteries and implanted in canine models. Prior
to cell seeding, BMCs were induced to differentiate in vitro
into SM -actin/SM myosin heavy-chain (SMMHC)–positive
cells and von Willebrand factor (vWF)/CD31-positive cells
by culturing BMCs in different types of media. Decellular-
ized arteries were used as scaffolds for vascular tissue recon-
struction because these scaffolds preserved biochemical com-
ponents and structures of native extracellular matrices
(ECMs) of blood vessels. The vascular tissue regeneration
and graft patency were examined.
MATERIALS AND METHODS
Preparation of Decellularized Vascular Matrix
Decellularized vascular matrices (3 mm in ID, 40 mm
in length) were prepared as previously described.13 In brief,
freshly harvested canine carotid arteries were washed with
distilled water for 1 hour to remove blood elements. The
vessels were then immersed in a decellularization solution
(0.5% (vol/vol) Triton X-100 (Sigma, St. Louis, MO) and
0.05% (vol/vol) ammonium hydroxide (Sigma) in distilled
water) with shaking at 4°C for 3 days. To remove the residual
detergent, the decellularized vessels were washed in distilled
water with shaking at 4°C for 3 days. The resultant matrices
were lyophilized for 1 day and sterilized with ethylene oxide
gas at room temperature.
BMC Isolation and Culture
Mongrel dogs (20–25 kg) were anesthetized, and bone
marrow (30 mL for each dog) was aspirated from the humeri
of the dogs and immediately mixed with heparin (100 unit
heparin/mL bone marrow). The mixture was centrifuged on a
Ficoll-Paque density gradient (Amersham Bioscience, Ar-
lington Heights, IL) for 20 minutes at 1500 rpm. BMMNCs
were isolated from the buffy coat layer between the Ficoll-
Paque reagent and blood plasma component and washed 3
times in phosphate-buffered saline (PBS; Sigma) solution.
BMMNC fraction for SM -actin/SMMHC-positive cells
was cultured in Medium 199 (Gibco BRL, Gaithersburg,
MD) containing 10% (vol/vol) fetal bovine serum (FBS), 1%
(wt/vol) penicillin and streptomycin (Gibco BRL). BMMNC
fraction for vWF/CD31-positive cells was cultured in EBM-2
(Clonetics, San Diego, CA) supplemented with human vas-
cular endothelial growth factor (VEGF; 10 ng/mL; Pepro-
Tech, Rocky Hill, NJ), human basic fibroblast growth factor
(bFGF; 2 ng/mL; PeproTech), human epidermal growth fac-
tor (10 ng/mL; PeproTech), human insulin-like growth fac-
tor-1 (5 ng/mL; PeproTech), and ascorbic acid on culture
dishes coated with 1 g/cm2 human fibronectin (Sigma). The
culture medium was changed every 2 days.
BMC Characterization
Cultured BMCs were stained immunohistochemically
using antibodies against SM -actin (DAKO, Carpenteria,
CA), SMMHC (DAKO), vWF (DAKO), and CD31 (DAKO).
The staining signal was developed with avidin-peroxidase
system (Vectastain Elite ABC kit; Vector Laboratories, Bur-
lingame, CA).
BMC Labeling
Cultured BMCs were labeled with 1 g/mL of Cell
Tracker chloromethyl-1,1-dioactadecyl-3,3,3,3-tetrameth-
ylindocarbocyanine perchlorate (CM-DiI; Molecular Probes,
Eugene, OR), a fluorescent carbocyanine dye, at 37°C for 5
minutes and then at 4°C for 15 minutes. The labeled cells
were washed 3 times with PBS and seeded onto decellular-
ized vascular matrices.
Cell Seeding Onto Vascular Matrix and in Vitro
Maintenance
SM -actin/SMMHC-positive cells and vWF/CD31-
positive cells differentiated from BMCs were cultured for 3
weeks to obtain enough cells for seeding onto the vascular
grafts. The cultured BMCs were passaged twice for 3-week
culture. SM -actin/SMMHC-positive cells were uniformly
seeded onto small-diameter decellularized matrices at a cell
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density of 3  107 cells/mL. Two hours later, vWF/CD31-
positive cells were then uniformly seeded onto the luminal
sides of the matrices at a cell density of 1  107 cells/mL.
The seeded grafts were maintained in vitro in Medium 199
supplemented with 20% (vol/vol) FBS, VEGF (10 ng/mL),
and bFGF (2 ng/mL) for 1 week prior to implantation. The
medium was changed every day. Intraluminal mechanical
supports for prevention of the graft lumen collapse were not
used.
Scanning Electron Microscopy
The explanted grafts were fixed in 1% (vol/vol) buff-
ered glutaraldehyde and 0.1% (vol/vol) buffered formalde-
hyde for 30 minutes and 24 hours, respectively, dehydrated
with a graded ethanol series, and dried. The dried samples
were mounted on aluminum stub and sputter-coated with
gold. Scanning electron microscope (JSM-6330F; JEOL, To-
kyo, Japan) was used to image the samples.
Suture Retention Strength Measurement
The suture retention strength of the vascular grafts was
measured using an Instron mechanical tester (Instron 4465;
Instron, Canton, MA) as previously described.26 One end of
the specimen was fixed by stage clamp of Instron tester, and
the other end was connected to another clamp by a suture
material (4–0 prolene; Ethicon, Somerville, NJ). The mea-
surement was performed using a 100-Newton maximum load
cell, and the cross-head speed was 10 mm/min. A tensile
force was applied until the grafts were completely torn off
and the graft rupture stress was recorded.
DNA Quantification
To determine whether the cellular components were
completely removed from the canine carotid arteries through
the decellularization process, the total DNA in the decellu-
larized matrices was quantified. DNA from tissues was iso-
lated using a Wizard Genomic DNA Purification kit (Pro-
mega, Madison, WI). The DNA content was determined with
ultraviolet absorbance spectrophotometry at 260 nm and
compared with the DNA content in the native canine carotid
arteries.
Surgical Implantation of Vascular Grafts
Bone marrow donor mongrel dogs (20–25 kg) were
anesthetized with injection of intramuscular ketamine (30
mg/kg) and intravenous pentobarbital (30 mg/kg) and venti-
lated with a mixture of O2, N2, and isoflurane during the
operation. Through a longitudinal midneck incision, common
carotid arteries were exposed. Prior to arterial clamping,
heparin (100 unit/kg; Choongwae Pharma Co, Seoul, Korea)
was administered intravenously. The grafts were placed as an
end-to-end anastomosis to the common carotid arteries using
a 6–0 Prolene suture (Ethicon). Decellularized grafts without
cell seeding served as controls. Prior to implantation, the
control grafts were rehydrated in PBS solution. The arterial
flow was reestablished and the closure was sutured by layers.
No anticoagulants or antiplatelets were administered postop-
eratively. The implanted graft patency was monitored by the
arterial digital subtraction angiography every week. All care
and handling of the animals were provided according to the
Guide for the Care and Use of Laboratory Animals of Yonsei
University.
Explant Characterization
Midportion segments of the grafts were fixed with 10%
(vol/vol) buffered formaldehyde solution and dehydrated
with a series of ethanol. The samples were embedded in
paraffin, sectioned 4 m in thickness, and stained with
hematoxylin and eosin (H&E). Elastin and collagen in the
explant tissue sections were stained with van Gieson method
and Masson trichrome method, respectively. The tissue sec-
tions were also stained immunohistochemically for vWF, SM
-actin, and SMMHC using avidin-peroxidase system (Vec-
tastain Elite ABC kit). CM-DiI-labeled cells in the tissue
sections were analyzed using a fluorescence microscope
(Eclipse E800; Nikon, Tokyo, Japan) before and after im-
plantation.
Statistical Analysis
Result data were expressed as mean  SD. Statistical
analysis was performed by unpaired Student t test using
InStat software (InStat 3.0; GraphPad Software Inc, San
Diego, CA). A value of P  0.05 was considered to be
statistically significant.
RESULTS
Decellularized Vascular Matrices
Decellularized canine carotid arteries 3 mm in ID and
40 mm in length were used as the vascular matrices (Fig. 1A).
Decellularized matrices were prepared by removing cellular
components from the canine carotid arteries and leaving the
native ECMs of the arteries. H&E staining revealed that the
vascular matrices processed with the decellularization tech-
nique were acellular (Fig. 1B). Histologic analysis (van
Gieson staining) confirmed that ECMs, such as internal
elastic lamina and external elastic lamellae, were well pre-
served in the decellularized vascular matrices (Fig. 1C). The
matrices exhibited porous structures (Fig. 1D), which would
be appropriate for cell seeding and adhesion. Endothelium
was not observed in the scanning electron micrographs (Fig.
1E). Mercury porosimetric analysis revealed that the porosity
of the decellularized matrices was 66.8%. The pore size was
mainly below 20 m in diameter (Fig. 1F). The microporous
structures of the matrices would be appropriate for migration
and ingrowth of seeded cells. Quantification of DNA content
in the decellularized arteries showed that almost all the
cellular components in the matrices were removed by the
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nonionic detergent treatment, as the DNA content in the
decellularized matrices was only 1.7% of that in the native
carotid arteries.
Vascular Cells from Bone Marrow
To differentiate BMCs into vWF/CD31-positive cells
and SM -actin/SMMHC-positive cells, BMCs were cultured
in each medium appropriate for either endothelial-like cell or
vascular SM-like cell differentiation. After 3 weeks in cul-
ture, the BMCs cultured in the medium for endothelial-like
cells showed cobblestone morphology, a characteristic of
ECs (Fig. 2A). In addition, these cells expressed vWF (Fig.
2B) and CD31 (Fig. 2C). The BMCs cultured in the medium
for SM-like cells showed SMC-like morphology (Fig. 2D)
and stained positively for SM -actin (Fig. 2E) and SMMHC
(Fig. 2F). These results demonstrate that endothelial-like and
SM-like cells for vascular tissue engineering can be obtained
from bone marrow.
Cell Seeding Onto Decellularized Vascular
Matrices and in Vitro Maintenance
Vascular cells derived from bone marrow were seeded
onto decellularized vascular matrices. BMCs cultured in the
medium for endothelial-like cells and medium for SM-like
cells were seeded onto intimal sides and outsides of the
decellularized vascular matrices, respectively. After seeding,
the seeded vascular grafts (Fig. 3A) were maintained in vitro
for 1 week to provide the cell adhesion to the grafts. Scanning
electron micrographic examination of the luminal surfaces of
the grafts revealed a confluent layer of endothelial-like cells
(Fig. 3B). Histologic cross-sections of the grafts confirmed
FIGURE 1. Characterization of a de-
cellularized vascular matrix. A, A gross
view of decellularized canine carotid
artery (length 40mm, ID 3mm).
The scale is in centimeters. B, H&E
staining showed complete removal
of cellular components from canine
carotid artery ( 100). C, van Gieson
elastin staining showed well-pre-
served elastin layers in the decellular-
izedmatrix ( 100). D, Scanning elec-
tron micrograph of the cross-section
of the matrix ( 200). E, Scanning
electron micrograph of the luminal
surface of the matrix ( 250). The
scale bars indicate 200 m. F, Pore
size distribution of the decellularized
matrix as determined by mercury
porosimetry. The average pore di-
ameter of the matrix was approxi-
mately 17.3 m.
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that most of the seeded cells were distributed near the intima
and adventitia of the vascular grafts (Fig. 3C).
Suture Retention Strength
To evaluate in vivo effectiveness of the vascular grafts,
implantation studies were performed in canine models. Prior
to implantation, the suture retention strength of the vascular
grafts was measured to determine whether the grafts could
withstand forces exerted in anastomosis. The average suture
retention strength of the vascular grafts was 606  98 g, and
it was not statistically different from that of the native canine
carotid arteries (753  112 g) (P 0.05) (Fig. 4), suggesting
that the vascular graft has sufficient suture retention strength
to withstand anastomosis forces. Practically, the vascular
grafts were anastomosed to carotid arteries in canine models,
without graft rupture (Fig. 5).
Graft Patency
Segments of the carotid arteries in bone marrow donor
dogs were replaced by seeded (n  6, autologous) and
unseeded (n  6, controls) vascular grafts (40 mm in length
and 3 mm in ID) using the end-to-end anastomosis. To
determine the graft patency, the animals were periodically
investigated by arterial digital subtraction angiography after
implantation (Fig. 6A, B). Patency of the vascular grafts was
significantly improved by BMC seeding. Out of the 6 un-
seeded control grafts, 4 and 2 grafts occluded by 1 and 2
weeks, respectively, with thrombus formation (Fig. 6C). In
contrast, the vascular graft seeded with autologous BMCs
maintained patency for up to 8 weeks (Fig. 6C).
Vascular Tissue Regeneration in vivo
Histologic analyses of the seeded vascular grafts at 8
weeks revealed regeneration of the 3 elements of artery
(endothelium, media, and adventitia). The H&E-stained sec-
tions showed reconstruction of the artery, with structures very
similar to those of the native artery (Fig. 7A). Two major
ECMs in the artery were present in the seeded vascular grafts
at 8 weeks. Elastin staining by van Gieson method displayed
internal elastic lamina and external elastic lamellae layers in
the vascular grafts (Fig. 7B). A significant amount of collagen
was present in the grafts, as evaluated by Masson trichrome
staining (Fig. 7C). The cells in the media stained positively
for SM -actin and SMMHC (Fig. 7D, E), both of which are
characteristics of SMCs, indicating regeneration of SM in the
media. The cells lining the lumen stained positively for vWF,
which is a characteristic of ECs (Fig. 7F). Scanning electron
microscopic examination also confirmed endothelium regen-
eration in the grafts (Fig. 7G).
Identification of Implanted BMCs
Next, we investigated if the seeded BMCs were still
present on the grafts at 8 weeks. Prior to seeding onto
vascular grafts, BMCs were labeled with a fluorescent li-
pophilic carbocyanine tracer (CM-DiI). Before implantation,
the vascular graft sections showed the presence of the labeled
BMCs (Fig. 8A). Eight weeks after implantation, the labeled
BMCs were found in the intima and media of the vascular
grafts (Fig. 8B, C), suggesting that implanted cells survived
and participated in the vascular tissue regeneration. Fluores-
cence intensity diminished probably due to migration of the
seeded cells to media and dilution of the cell membrane
incorporated dye with cell division.
DISCUSSION
The present study reports the first attempt to develop
small-diameter vascular grafts using tissue-engineering tech-
nique and bone marrow–derived mesenchymal stem cells.
BMCs were induced to differentiate in vitro into SM -actin/
SMMHC-positive cells (SM-like cells) and vWF/CD31-pos-
itive cells (endothelial-like cells), and seeded onto decellu-
larized canine carotid arteries. Upon implantation, the
vascular grafts showed regeneration of the 3 elements of the
FIGURE 2. Characterization of cultured bone marrow–derived
cells (BMCs). A, BMCs expanded in endothelial-like cell culture
condition showed cobblestone morphology of typical ECs (
100). Cultured endothelial-like cells stained positively for (B)
vWF ( 100) and (C) CD31 ( 400), which are EC markers. D,
BMCs expanded in SM-like cell culture condition had morphol-
ogy similar to that of mature SMCs ( 100). Cultured SM-like
cells expressed (E) SM -actin ( 100) and (F) SMMHC ( 100),
which are SMC markers. The scale bars indicate 10 m.
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artery (endothelium, media, and adventitia). Importantly,
BMC seeding has been found to significantly improve the
patency of the tissue-engineered small-diameter (ID 3 mm)
vascular grafts.
Decellularized matrices would be ideal scaffolds for
vascular tissue reconstruction. First, decellularized matrices
retain native ECMs of blood vessels. Histologic analyses,
such as H&E and elastin staining, showed that the structural
integrity of the native ECM architecture was well preserved
in the matrices (Fig. 1B, C). Decellularization process using
FIGURE 5. Surgical implantation of the tissue-engineered vas-
cular grafts. The grafts were interposed to common carotid
arteries by the end-to-end anastomosis in canine models. The
arrowheads indicate the anastomotic sites.
FIGURE 3. Examination of cell-seeded vascular grafts prior to
implantation. A, A gross view of a tissue-engineered vascular
graft 1 week after BMC seeding. The scale is in centimeters. B,
Scanning electron micrograph of the luminal surface of the
vascular graft 1 week after cell seeding ( 500). C, H&E
staining of the vascular graft 1 week after cell seeding indi-
cated that most of the seeded cells were distributed near the
intima and adventitia of the scaffold ( 100). The scale bars in
(B) and (C) indicate 30 m and 200 m, respectively.
FIGURE 4. Suture retention strength measurement of the
tissue-engineered vascular grafts. The average value of the
tissue-engineered vascular grafts (n  4) is slightly lower than
that of the native canine carotid arteries (n  4), but the
difference is not statistically significant (P  0.05).
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nonionic detergent (Triton X-100), which was used in this
study, produces a matrix primarily composed of elastin and
insoluble collagen.27 These structural proteins of decellular-
ized matrix could provide physiologically proper microenvi-
ronment for vascular cell repopulation.28 Through scanning
electron microscopic and histologic analyses of the cell-
seeded grafts performed prior to implantation, the BMCs
were distributed throughout the matrices, and decellularized
matrices were confirmed to efficiently work as scaffolds for
cell adherence. Second, decellularized matrices may not show
immune rejection in vivo. Because cellular components are
removed from tissues, the resultant decellularized matrices
may not possess antigenic determinants which elicit immune
response.29 Several studies have reported that allogenic de-
cellularized matrices showed low immunogenicity in
vivo.29,30 Third, decellularized matrices have good mechan-
ical properties and handling characteristics. Mechanical prop-
erties of artificial vascular grafts are critical for the long-term
patency of the grafts.31 In particular, mismatching of the
elasticity between the grafts and the native blood vessels may
cause intimal hyperplasia and lead to graft occlusion.32 A
previous study has shown that decellularized porcine carotid
FIGURE 6. Angiogram and patency of the implanted tissue-
engineered vascular grafts and control grafts. A, Angiogram of
the BMC-seeded vascular grafts 8 weeks after implantation:
the grafts maintain patency without occlusion. B, Angiogram
of the control grafts (decellularized matrices with no cell
seeding) 2 weeks after implantation: the grafts completely
occluded within 2 weeks after implantation and showed no
blood flow. C, Patency of the implanted tissue-engineered
vascular grafts and control grafts. The vascular grafts engi-
neered with BMCs (n  6, dotted line) maintained patency for
up to 8 weeks, whereas all control groups (n  6, solid line)
occluded within 2 weeks. FIGURE 7. Histologic, immunohistochemical, and scanning
electron microscopic evaluations of the BMC-seeded vascular
grafts retrieved 8 weeks after implantation. A, H&E staining of
the retrieved grafts demonstrated regeneration of the 3 ele-
ments of artery (endothelium, media, and adventitia) ( 100).
B, van Gieson elastin staining showed well-preserved elastin
layers. Black wiggly lines are elastin layers (arrows,  100). C,
Masson trichrome staining indicated collagen (blue) between
elastin layers ( 100). Immunostaining for (D) SM -actin (
400) and (E) SMMHC ( 400) showed the presence of SMCs
(brown) in medial layers. F, Cells lining the lumen of the retrieved
grafts stained positively for vWF (arrows, brown line,  400).
Scale bars in (A) through (F) indicate 100 m. G, Scanning
electron micrograph of the lumen of the retrieved grafts
showed endothelium formation ( 800). The scale bar in (G)
indicates 30 m.
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arteries are similar to native arteries in compliance and burst
strength.33 In the present study, the suture retention strength
tests have verified that the vascular grafts constructed from
decellularized matrices have an appropriate mechanical
strength that enables them to endure forces exerted by sutures
during surgery, suggesting that they can be anastomosed
without graft rupture. The average suture retention strength of
the vascular grafts was approximately 600 g, which is con-
sidered to be a value sufficient for clinical use. This value is
much higher than that of the vascular grafts tissue-engineered
from biodegradable synthetic polymers.12,26 Therefore, de-
cellularized matrices may be more appropriate scaffold for
vascular graft than synthetic polymeric matrices. Since the
mechanical properties of cell-seeded grafts would be contrib-
uted by the ECMs rather than the seeded cells, the mechanical
properties of the decellularized matrices would be similar to
those of the cell-seeded grafts.
This study showed that the vascular cells exhibiting EC
and SMC phenotypes could be induced from BMCs. These
results are consistent with those of previous studies demon-
strating that endothelial-like and SM-like cells could be
derived from BMCs in vitro.16,17,20,21 There have been evi-
dences from animal studies that BMCs contain endothelial
and SM progenitor cells. EPCs mobilized from bone marrow
by cytokine induction have been reported to enhance angio-
genesis and neovascularization in ischemic tissues.18,19 In
addition, several studies have shown that intimal SMCs
contributing to vascular diseases may be derived from
BMCs.22,23 These results suggest that BMCs could be a cell
source for EC and SMC.
BMCs would be an ideal cell source for tissue engi-
neering of autologous vascular grafts. Bone marrow aspira-
tion would be less invasive and associated with much lower
morbidity at the donor sites than blood vessel biopsy for cell
isolation. In addition, BMCs could be used as a cell source
when patients do not have blood vessels suitable for biopsy
due to preexisting vascular diseases or blood vessel use in
previous procedures. Using patients’ own BMCs, autologous
vascular grafts could be constructed. A clinical case report
demonstrated the feasibility of tissue engineering of large-
diameter vascular grafts with autologous BMMNCs in hu-
mans.34 In addition, cell therapy using autologous BMMNCs
or bone marrow AC133-positive cells has been clinically
tested in humans for neovascularization in limb ischemic
tissues35 or cardiac regeneration in infarcted myocardium.36
These results demonstrate the applicability of BMCs as an
autologous cell source in clinical therapy in cardiovascular
diseases.
This is the first report of using BMCs for tissue engi-
neering of autologous small-diameter vascular graft. In this
study, BMCs implantation onto decellularized vascular ma-
trices (ID  3 mm) has improved the graft patency signifi-
cantly and regenerated vascular tissues in vivo. Recent tissue-
engineering approaches have also demonstrated the
feasibility of using BMCs to construct autologous vascular
grafts. Autologous canine BMMNCs seeded onto large-diam-
eter (ID  8 mm) biodegradable polymer matrices formed
vascular tissues in vivo.24 Nondegradable polymer vascular
grafts (ID  8 mm) seeded with bone marrow CD34-positive
cells showed higher endothelialization than nonseeded grafts
in a canine model.25 However, these previous studies have
dealt with tissue engineering of large-diameter vascular grafts
(ID  6 mm), and no study has yet reported on engineering
of small-diameter vascular grafts with BMCs in vivo.
The patency of the vascular grafts developed in this
study needs to be further improved. Although the grafts
engineered with BMCs have shown an improved patency
compared with nonseeded grafts, occlusion due to thrombus
formation has been noted even in grafts engineered with
BMCs. The graft occlusion might be due to detachment of
endothelial-like cells from the lumen sides of the grafts after
implantation in vivo or incomplete endothelialization. It was
reported that up to 80% of the seeded ECs were detached
from the ePTFE vascular grafts when ECs on the grafts were
exposed to blood flow without preconditioning.37 Cell seed-
ing and in vitro graft maintenance in a static culture condition
may be inefficient methods for formation of functional endo-
thelium that can endure in vivo arterial conditions with high
shear stress. Dynamic cell seeding on scaffolds38 and precon-
ditioning of the seeded scaffolds13,39 in pulsatile bioreactor
FIGURE 8. Identification of implanted BMCs in the tissue-
engineered vascular grafts retrieved 8 weeks after implanta-
tion. A, Before implantation, the BMCs labeled with fluores-
cent cell tracer (CM-DiI) were layered mainly on the luminal
sides of the vascular grafts ( 400). The CM-DiI-labeled BMCs
were detected on (B) the intimal parts ( 400) and (C) the
medial parts ( 400) of the grafts retrieved 8 weeks after
implantation. The scale bars indicate 50 m.
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may improve functional endothelium formation in vitro and
the graft patency in vivo. In addition, several studies have
reported that systemic administration of granulocyte colony-
stimulating factor (G-CSF) enhanced vascular graft endothe-
lialization in vivo.40,41 G-CSF has been known to mobilize
EPCs in bone marrow and increase EPC numbers in the
circulation.42 Therefore, G-CSF treatment could be consid-
ered as a complement to the improvement of the tissue-
engineered vascular graft patency.
In summary, this study showed tissue engineering of
small-diameter (ID  3 mm) vascular grafts using BMCs.
The vascular grafts engineered with vascular cells (endothe-
lial-like cells and SM-like cells) induced from autologous
BMCs showed vascular tissue regeneration and significant
patency improvement. Additional studies will be necessary to
determine whether the grafts show endothelium functionality,
vasoreactivity, and aneurysmal dilation in long-term implan-
tation. Followed by improvement in endothelialization meth-
ods for the improved graft patency, this approach may sug-
gest the possibility of constructing functional small-diameter
vascular grafts.
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